Sign In
Buy ASMB
$27.74
+1.05 (+3.93%)
At Close: Jul 02, 2026
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
01:04pm, Monday, 08'th Jun 2026
Assembly Biosciences NASDAQ: ASMB outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming dec
Assembly Biosciences, Inc. (ASMB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
12:38pm, Monday, 08'th Jun 2026
Assembly Biosciences, Inc. (ASMB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands
03:03pm, Friday, 05'th Jun 2026
Assembly Biosciences NASDAQ: ASMB is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications
Assembly Biosciences Announces Upcoming Investor Conference Presentations
04:05pm, Thursday, 28'th May 2026
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver di
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver di
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
07:05am, Friday, 22'nd May 2026
SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver di
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
07:00am, Friday, 22'nd May 2026
– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 – – Builds on completed Phase 1a study and ongoing development in HDV –
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference
07:06am, Thursday, 14'th May 2026
Assembly Biosciences NASDAQ: ASMB Chief Medical Officer Anuj Gaggar outlined the company's virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing pr
Assembly Biosciences, Inc. (ASMB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
09:20pm, Wednesday, 13'th May 2026
Assembly Biosciences, Inc. (ASMB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
02:00am, Wednesday, 13'th May 2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, to
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
08:00am, Monday, 11'th May 2026
SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, to
Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue Estimates
06:16pm, Thursday, 07'th May 2026
Assembly Biosciences (ASMB) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to a loss of $1.17 per share a year ago.
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
04:00pm, Thursday, 07'th May 2026
– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule ent
– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentatio
Brokerages Set Assembly Biosciences, Inc. (NASDAQ:ASMB) PT at $41.75
01:12am, Saturday, 21'st Mar 2026
Assembly Biosciences, Inc. (NASDAQ: ASMB - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the stock, MarketBeat Ratings reports.
